[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Questions for FDA", "description": "Peter Doshi, senior editor, The BMJ\n\nThe FDA should demand adequate, controlled studies with long term follow up, and make data publicly available, before granting full approval to covid-19 vaccines\n\nhttps://blogs.bmj.com/bmj/2021/08/23/does-the-fda-think-these-data-justify-the-first-full-approval-of-a-covid-19-vaccine/\n\nPfizer press release, 1 April, 2021\n\nhttps://investors.pfizer.com/investor-news/press-release-details/2021/Pfizer-and-BioNTech-Confirm-High-Efficacy-and-No-Serious-Safety-Concerns-Through-Up-to-Six-Months-Following-Second-Dose-in-Updated-Topline-Analysis-of-Landmark-COVID-19-Vaccine-Study/default.aspx\n\nBNT162b2 is highly effective with 91.3% vaccine efficacy\n\nData cut-off date was 13 March\n\nmeasured seven days through up to six months after the second dose\n\nSix Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine, (Published 28 July)\n\nhttps://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1\n\nOngoing phase 3 covid-19 vaccine trial\n\nVE against COVID-19 was 91% (95% CI 89.0-93.2) through up to 6 months of follow-up, \n\nThe current report provides updated efficacy analyses conducted on cases accrued up to March 13, 2021.\n\nEfficacy, an average decline of ~6% every 2 months\n\nFDA Approves First COVID-19 Vaccine, (23rd August)\n\nhttps://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine\n\nBased on results from the clinical trial, the vaccine was 91% effective in preventing COVID-19 disease.\n\nNew COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status \u2014 New York, May 3\u2013July 25, 202, (Published 18th August)\n\nhttps://www.cdc.gov/mmwr/volumes/70/wr/mm7034e1.htm?s_cid=mm7034e1_w\n\n(NY data)\n\nProtection against infection\n\nJuly 25, 79.8%\n\nAge adjusted effectiveness against hospitalizations\n\nJuly 25, 91.9% to 95.3%\n\nDuring May 3\u2013July 25, 2021, the overall age-adjusted VE against new COVID-19 cases for all adults declined from 91.7% to 79.8%. \n\nDuring the same period, the overall age-adjusted VE against hospitalization was relatively stable, ranging from 91.9% to 95.3%.\n\nIsrael sees drop in Pfizer vaccine protection against infections\n\nhttps://www.reuters.com/world/middle-east/israel-sees-drop-pfizer-vaccine-protection-against-infections-still-strong-2021-07-05/\n\nVaccine effectiveness in preventing both infection and symptomatic disease fell to 64% since June 6\n\nIsrael says Pfizer Covid vaccine is just 39% effective as delta spreads, but still prevents severe illness\n\nhttps://www.cnbc.com/2021/07/23/delta-variant-pfizer-covid-vaccine-39percent-effective-in-israel-prevents-severe-illness.html\n\nData from June 20 and July 17\n\nPfizer sales\n\nhttps://www.bmj.com/content/374/bmj.n2096\n\nhttps://www.fiercepharma.com/pharma/pfizer-now-expects-covid-19-vaccine-sales-33-5b-a-7-5b-increase-from-3-months-ago\n\nThe company now predicts 2021 sales of $33.5 billion\n\nPfizer and BioNTech now expect to deliver 2.1 billion doses of Comirnaty worldwide this year and manufacture 3 billion. \n\n(at average price of $15.95)\n\n2022 production capacity at 4 billion doses", "link": "https://www.youtube.com/watch?v=WOtvpk9rZLs", "date_published": "2021-08-25 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "FDA full approval for Pfizer", "description": "FDA Approves First COVID-19 Vaccine\n\nEUA since December 11, 2020\n\nhttps://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine\n\nU.S. Food and Drug Administration\n\nPfizer-BioNTech COVID-19 Vaccine\n\nWill now be marketed as Comirnaty (koe-mir\u2019-na-tee)\n\nfor the prevention of COVID-19 disease in individuals 16 years of age and older\n\nContinues to be available under emergency use authorization (EUA), 12 to 15s\n\nand for a third dose in immunocompromise\n\nActing FDA Commissioner Janet Woodcock, M.D\n\nWhile this and other vaccines have met the FDA\u2019s rigorous, scientific standards for emergency use authorization, \n\nas the first FDA-approved COVID-19 vaccine, the public can be very confident that this vaccine meets the high standards for safety, effectiveness, and manufacturing quality the FDA requires of an approved product\n\nwe recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated. \n\nToday\u2019s milestone puts us one step closer to altering the course of this pandemic in the U.S.\n\nFDA statement\n\nThe mRNA in Comirnaty is only present in the body for a short time and is not incorporated into - nor does it alter - an individual\u2019s genetic material. \n\nComirnaty has the same formulation as the EUA vaccine and is administered as a series of two doses, three weeks apart.\n\nAnalyzed effectiveness and safety data from 20,000 vaccine and 20,000 placebo recipients\n\nVaccine was 91% effective in preventing COVID-19 disease\n\nSafety, approximately 12,000 recipients have been followed for at least 6 months.\n\nThe most commonly reported side effects\n\nPain, redness and swelling at the injection site\n\nFatigue, headache, muscle or joint pain, chills, and fever\n\nRigorous evaluation of the post-authorization safety surveillance data\n\nMyocarditis and pericarditis\n\nChest pain, shortness of breath, or feelings of having a fast-beating, fluttering, or pounding heart\n\nhttps://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-june-25-2021\n\nhttps://www.cdc.gov/mmwr/volumes/70/wr/mm7027e2.htm\n\n52 million doses to 12\u201329 years\n\n1,226 reports of myocarditis after mRNA vaccination 42,414\n\nOne in 42,414\n\nData demonstrate increased risks, particularly within the seven days following the second dose\n \nThe observed risk is higher among males under 40 years of age compared to females and older males\n\nRisk is highest in males 12 through 17 years of age\n\nShort-term follow-up suggest that most individuals have had resolution of symptoms\n\nSome individuals required intensive care support\n\nInformation is not yet available about potential long-term health outcomes\n\nFDA and CDC, monitoring systems in place for early detection\n\nPfizer will\n\nConduct postmarketing studies to further assess the risks of myocarditis and pericarditis\n\nInclude an evaluation of long-term outcomes\n\nConducting a pregnancy registry study to evaluate pregnancy and infant outcomes after vaccination during pregnancy", "link": "https://www.youtube.com/watch?v=knFLwOnoo0M", "date_published": "2021-08-24 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]